SGLT2 treatment improves outcomes in patients without diabetes
Researchers from a new meta-analysis of data report that, in addition to its known benefits, sodium glucose co-transporter-2 inhibitor (SGLT2) treatment reduces the risk of adverse kidney and… read more.